Metformin is commonly used as first-line therapy unless contraindicated or poorly tolerated, but the addition of glucose-lowering therapies with different mechanisms of action is usually needed to provide adequate glycemic control [1,2,3], with the choice of agent being dependent on multiple factors, such as cost and the presence of comorbidities [1]
Approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, it demonstrated remarkable efficacy in the SURMOUNT-1 clinical trial, where participants achieved 16 to 22.5 percent body weight loss over 72 weeks depending on dose
Pharmaceutical manufacturers need to do a lot of testing to get FDA approval
If you are using compounded tirzepatide, the date may be listed as a Beyond Use Date or BUD
Your provider will determine the appropriate maintenance dose based on how your body responds, your weight loss trajectory, and your side effect profile